Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 14/20 | 1.00 |
| ▸ | USP47 | Q96K76 | 6/20 | 1.00 |
| ▸ | USP10 | Q14694 | 1/20 | 1.00 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493045 | 1.00 | USP7 (1.00) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680882 | 0.89 | USP7 (0.80) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2681306 | 0.87 | USP7 (0.77) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680442 | 0.79 | USP7 (0.65) | USP7USP47USP10PADI4 | |
| SCHEMBL2680726 | 0.78 | USP7 (1.00) | USP7USP47USP10PADI4TDP1 | |
| SCHEMBL25465158 | 0.78 | USP7 (0.63) | USP7USP47USP10PADI4KDM4E | |
| SCHEMBL21123615 | 0.78 | USP7 (0.63) | USP7USP47USP10PADI4ATM | |
| SCHEMBL2680611 | 0.77 | USP7 (0.71) | USP7USP47USP10PADI4TDP1 | |
| SCHEMBL2680825 | 0.77 | USP7 (1.00) | USP7USP47USP10PADI4TDP1 | |
| SCHEMBL17059890 | 0.76 | USP7 (1.00) | USP7USP47USP10ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016004915-A1 | SUBSTANCES FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | IMMUNOLOGIK GMBH (DE) | 2016-01-14 | — | — | WO | claimed |
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | claimed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | claimed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | claimed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3472303-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014194312-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF TO TREAT RECURRENT MALIGNANT GLIOMA OR PROGRESSIVE SECONDARY BRIAN TUMOR | DEL MAR PHARMACEUTICALS (CA) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014168986-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2014-10-16 | — | — | WO | disclosed |
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | USP7 2697/4885USP47 2383/4885USP10 3042/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | USP7 2697/4885USP47 2383/4885USP10 3042/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | USP7 2697/4885USP47 2383/4885USP10 3042/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | USP7 39/4885USP47 270/4885USP10 888/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | USP7 958/4885USP47 633/4885USP10 1001/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | USP7 2697/4885USP47 2383/4885USP10 3042/4885 |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | USP7 437/4885USP47 315/4885USP10 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.